|Thursday, 21 February 2019, 13:50 HKT/SGT|
TOKYO, Feb 21, 2019 - (JCN Newswire) - AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant], "HUMIRA"), a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa (HS). With this approval, HUMIRA has become the first treatment indicated for HS in Japan, and is now approved for 11 indications in Japan.
The approval of this additional indication is based on the data from a Japanese Phase III study(1) and overseas clinical trials.(2) In these trials, the efficacy and safety of HUMIRA were evaluated in patients with moderate to severe HS. In the clinical trial conducted in Japan, the percentage of patients who achieved the primary endpoint of HiSCR* at Week 12 after treatment was 13 of 15 patients.3 In the same trial, adverse drug reactions (ADRs) were observed in 6 of 15 patients at Week 24 of treatment; ADRs observed in two or more patients were nasopharyngitis and cellulitis, and other ADRs including dental caries, erythrasma, folliculitis, lymphocyte count increased, erythema, pruritus, and skin exfoliation were observed in one patient each.(3)
HS is a painful, inflammatory skin disease with a chronic course which typically presents after puberty. Inflammatory symptoms are frequently observed in the axillary, inguinal, breast-fold, and gluteal regions. The main symptom is red, swollen boil-like lumps, and the progression of symptoms leads to formation of nodules, abscesses, and even fistulas. Repeated recurrence causes thickening of the affected areas, resulting in scarring.(4) Severe symptoms may limit the patients' daily activities and sometimes force them to stop working.(5) The epidemiology data in Japan is unknown,(6) and the prevalence outside Japan is reported to be 1%.(7) Since the disease is poorly recognized and difficult to diagnose, overseas reports indicate that the average time to definitive diagnosis is seven years, which is longer than that of psoriasis and other inflammatory skin diseases, and patients with HS visit hospitals more often.
"This approval will be a major step for patients with HS. HS is a recurrent disease with pain and pus discharge. It has a significant impact on patients' quality of life, affecting their work or study performance and, in advanced cases, requiring major surgery with skin grafting," said Dr. Tadashi Terui, Professor, Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine. "Only limited options have been available for the treatment of HS until now. The additional indication of HUMIRA for HS is expected to significantly contribute to the improvement in patients' quality of life."
AbbVie and Eisai will continue to promote and provide information on the proper use of HUMIRA while making further contributions to improve the quality of life of patients.
* HiSCR stands for Hidradenitis Suppurativa Clinical Response, and is defined as at least a 50% reduction from baseline in the abscess and inflammatory nodule counts, with no increase in abscess or draining-fistula counts.
(1) ClinicalTrials.gov Identifier: NCT02904902
(2) ClinicalTrials.gov Identifier: NCT01468207, NCT01468233
(3) Annual Meeting of the Tokyo Division of JDA, 2nd December, 2018
(4) Hunger RE, et al. Dermatology. 2017 Jul 7. doi: 10.1159/000477459.
(5) Jemec G. Clinical and experimental dermatology. , 1996, Vol.21(6), p.419-423
(6) Nobukazu Hayashi et.al., Journal of the Japan Organization of Clinical Dermatologists, 35 (4) ;601-609, 2018
(7) Revuz J., J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98.
HUMIRA is a fully human anti-TNF-alpha; monoclonal antibody formulation. In Japan, it is approved for the indications of "the treatment of rheumatoid arthritis (including inhibition of the progression of structural damage), the treatment of plaque psoriasis, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis,** intestinal Behcet's disease, non-infectious uveitis, posterior uveitis or panuveitis, induction and maintenance therapy for moderate to severely active Crohn's disease (administer HUMIRA to patients who have had an inadequate response to conventional therapy), and treatment of moderate to severe ulcerative colitis (administer HUMIRA to patients who have had an inadequate response to conventional therapy)."
** HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL are yet to be approved for this indication.
Only HUMIRA for Subcutaneous Injection 20 mg Syringe 0.4 mL and HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL are approved for this indication.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com
Public Relations Department,
Eisai Co., Ltd.
Feb 21, 2019 13:50 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|May 17, 2019 15:34 HKT/SGT|
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets|
|May 16, 2019 07:37 HKT/SGT|
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting|
|May 10, 2019 12:34 HKT/SGT|
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan|
|May 10, 2019 11:55 HKT/SGT|
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401|
|May 9, 2019 11:33 HKT/SGT|
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions|
|May 9, 2019 11:06 HKT/SGT|
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform|
|May 8, 2019 08:37 HKT/SGT|
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research|
|May 1, 2019 08:09 HKT/SGT|
Eisai Buys Out Purdue Rights to End Collaboration|
|Apr 24, 2019 16:53 HKT/SGT|
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting|
|Apr 24, 2019 08:36 HKT/SGT|
Eisai Selected as Competitive ICT Strategy Company for 2019|
|More news >>|